$0.50
-0.04 (-7.30%)
Open$0.86
Previous Close$0.54
Day High$0.88
Day Low$0.47
52W High$4.99
52W Low$0.28
Volume—
Avg Volume162.3K
Market Cap19.01M
P/E Ratio—
EPS$-1.45
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+3,070.5% upside
Current
$0.50
$0.50
Target
$15.90
$15.90
$11.92
$15.90 avg
$19.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.64M | 3.84M | 3.77M |
| Net Income | 720.4K | 800.4K | 930.4K |
| Profit Margin | 19.8% | 20.8% | 24.7% |
| EBITDA | 1.38M | 1.54M | 1.32M |
| Free Cash Flow | 559.4K | 545.0K | 561.2K |
| Rev Growth | +15.7% | +20.7% | +9.8% |
| Debt/Equity | 0.34 | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |